Editas Medicine $231 million stock offering
Davis Polk advised the joint book-running managers in connection with the $231 million common stock offering of 3,500,000 shares of common stock of Editas Medicine, Inc.The common stock is listed on the Nasdaq Global Select Market under the symbol “EDIT.”
Based in Cambridge, Massachusetts, Editas Medicine is a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases.
The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Katia Brener and associates Dennis Chu and Adam Greene. The intellectual property and technology transactions team included partner David R. Bauer and associates Christopher C. Woller and Hilary Smith. All members of the Davis Polk team are based in the New York office.